Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/110178
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Bell's Palsy in Children (BellPIC): protocol for a multicentre, placebo-controlled randomized trial
Author: Babl, F.
Mackay, M.
Borland, M.
Herd, D.
Kochar, A.
Hort, J.
Rao, A.
Cheek, J.
Furyk, J.
Barrow, L.
George, S.
Zhang, M.
Gardiner, K.
Lee, K.
Davidson, A.
Berkowitz, R.
Sullivan, F.
Porrello, E.
Dalziel, K.
Anderson, V.
et al.
Citation: BMC Pediatrics, 2017; 17(1):53-1-53-11
Publisher: BioMed Central
Issue Date: 2017
ISSN: 1471-2431
1471-2431
Statement of
Responsibility: 
Franz E. Babl, Mark T. Mackay, Meredith L. Borland, David W. Herd, Amit Kochar, Jason Hort, Arjun Rao, John A. Cheek, Jeremy Furyk, Lisa Barrow, Shane George, Michael Zhang, Kaya Gardiner, Katherine J. Lee, Andrew Davidson, Robert Berkowitz, Frank Sullivan, Emily Porrello, Kim Marie Dalziel, Vicki Anderson, Ed Oakley, Sandy Hopper, Fiona Williams, Catherine Wilson, Amanda Williams, Stuart R Dalziel, and for the PREDICT, Paediatric Research In Emergency Departments International Collaborative, research network
Abstract: Background: Bell's palsy or acute idiopathic lower motor neurone facial paralysis is characterized by sudden onset paralysis or weakness of the muscles to one side of the face controlled by the facial nerve. While there is high level evidence in adults demonstrating an improvement in the rate of complete recovery of facial nerve function when treated with steroids compared with placebo, similar high level studies on the use of steroids in Bell's palsy in children are not available. The aim of this study is to assess the utility of steroids in Bell's palsy in children in a randomised placebo-controlled trial. Methods/Design: We are conducting a randomised, triple-blinded, placebo controlled trial of the use of prednisolone to improve recovery from Bell's palsy at 1 month. Study sites are 10 hospitals within the Australian and New Zealand PREDICT (Paediatric Research in Emergency Departments International Collaborative) research network. 540 participants will be enrolled. To be eligible patients need to be aged 6 months to < 18 years and present within 72 hours of onset of clinician diagnosed Bell's palsy to one of the participating hospital emergency departments. Patients will be excluded in case of current use of or contraindications to steroids or if there is an alternative diagnosis. Participants will receive either prednisolone 1 mg/kg/day to a maximum of 50 mg/day or taste matched placebo for 10 days. The primary outcome is complete recovery by House-Brackmann scale at 1 month. Secondary outcomes include assessment of recovery using the Sunnybrook scale, the emotional and functional wellbeing of the participants using the Pediatric Quality of Life Inventory and Child Health Utility 9D Scale, pain using Faces Pain Scale Revised or visual analogue scales, synkinesis using a synkinesis assessment questionnaire and health utilisation costs at 1, 3 and 6 months. Participants will be tracked to 12 months if not recovered earlier. Data analysis will be by intention to treat with primary outcome presented as differences in proportions and an odds ratio adjusted for site and age. Discussion: This large multicenter randomised trial will allow the definitive assessment of the efficacy of prednisolone compared with placebo in the treatment of Bell's palsy in children.
Keywords: Bell’s palsy; facial nerve palsy; prednisolone; randomised controlled trial; child; House Brackmann scale
Rights: © 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
RMID: 0030078398
DOI: 10.1186/s12887-016-0702-y
Grant ID: http://purl.org/au-research/grants/nhmrc/1078069
http://purl.org/au-research/grants/nhmrc/1058560
Appears in Collections:Paediatrics publications

Files in This Item:
File Description SizeFormat 
hdl_110178.pdfPublished version494.5 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.